view more
MIAMI - A new multi-center clinical study is shedding light on a potential new approach for patients with advanced kidney cancer, offering measurable clinical responses alongside a clearer view into how the disease operates beneath the surface.
Findings from the ARC-20 phase 1 clinical trial show that casdatifan, an oral investigational therapy designed to inhibit hypoxia-inducible factor-2 alpha, produced durable tumor responses with a manageable safety profile in patients with heavily pretreated clear cell renal cell carcinoma, the most common form of kidney cancer. The study appears in Nature.
For a disease that often adapts and resists treatment, the results provide an early signal that a more targeted approach may help slow its momentum.
“These findings are encouraging and suggest we may be able to better understand which patients benefit from targeting this pathway,” said co-author of the study, Jamie Merchan, M.D., co-leader of the Translational and Clinical Oncology Research Program at Sylvester Comprehensive Cancer Center, part of University of Miami Miller School of Medicine, and director of its Phase 1 Clinical Trials Program.
